The GMALL B ALL/NHL 2002 protocol yields high rates of durable response in high grade B cell lymphoma

The front-line treatment of High-Grade B Cell lymphoma (HGBCL) still represents a significant clinical challenge, without a consensus on the current standard of care [ 1 , 2 ]. Prospective trials have more often pooled HGBCL with Diffuse Large B-Cell Lymphomas (DLBCL) thus clinical practice recommendations rely mainly on subset analysis and cohort extrapolations. Current treatment approaches for HGBCL include intensified chemotherapy programs such as CODOX-M-IVAC or R-DA EPOCH with survival rates ranging from 60% to 90%. However, a comparative analysis of trials is difficult due to different inclusion criteria and the small numbers of patients included [ 3 , 4 , 5 , 6 ].